Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 4Breast Neoplasms 3Uterine Cervical Neoplasms 1Stomach Neoplasms 1Risk Reduction Behavior 1Patient Preference 1Patient Acceptance of Health Care 1Health Behavior 1Esophageal Neoplasms 1Diabetes Mellitus 1Coronary Disease 1Behavior 1Barrett Esophagus 1Adenocarcinoma Of Esophagus 1

Interventions

Oxaliplatin 200Capecitabine 116S 1 (combination) 106Fluorouracil 105Docetaxel 100Cisplatin 88Leucovorin 75Paclitaxel 71Irinotecan 68apatinib 43sintilimab 42Drug Therapy 42Surgical Procedures, Operative 37Hyperthermic Intraperitoneal Chemotherapy 34pembrolizumab 32Radiotherapy 31Trastuzumab 30Gastrectomy 23Nivolumab 22Epirubicin 22Tegafur 21Bevacizumab 21XELOX 20titanium silicide 19camrelizumab 19tislelizumab 17Ramucirumab 17Carboplatin 16Neoadjuvant Therapy 15Endoscopic Mucosal Resection 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Stomach Neoplasms × Risk Assessment × Clear all
NCT06306755 2025-01-24

ERSS-EGC

Peking University Cancer Hospital & Institute

Phase NA Recruiting
21,000 enrolled
Gastrointestinal

Esophageal Neoplasms, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡